Data from the SOLAR-1 trial has shown a clear benefit in terms of prolonged progression-free survival in patients with PIK3CA mutated advanced breast cancers treated with both alpelisib and fulvestrant, compared to fulvestrant alone17. This evidence concerns the gene PIK3CA and breast cancer.